The Ibogaine Dossier
Art Buro, Amsterdam
Prepared for ICASH
for Addict Self-Help
The late Nico Adriaans.
Human being, harm reduction worker and activist.
Nico had a way with words.
"People expect I will introduce
as a heroin addict. Would you introduce
yourself and say, Hello I'm a coffee drinker?"
Rise and Fall of Addiction
© G. Frenken
What's new |
2009 International Drug Policy Reform Conference
Albuquerque Convention Center -- Albuquerque, New Mexico
November 11 - 14, 2009
Ibogaine: Medical Practice, Science, and African Heritage
Saturday, November 14, 2009, 3:00 PM - 4:30 PM
Room - Sleta / Jemez
Howard Lotsof -- Dora Weiner Foundation, Staten Island, NY - Mr. Lotsof is the recipient of this
year's Robert Randall Award for Achievement in the Field of Citizen Action
Ibogaine in opioid detoxification: How do we know it works? How does it
(The most often asked patient question)
Kenneth Alper, M.D. -- Associate Professor of Psychiatry and Neurology -- New York University
School of Medicine. USA presentation slide show
ppt Select slide show viewing mode.
Safety Issues and Cardiac Side-Effects in the Administration of Ibogaine HCl, as an Addiction Interrupter Drug.
What we know, what we theorize and what we don't know.
Jeffrey D. Kamlet, MD, FASAM, DABAM -- Fellow, American Society of Addiction Medicine. USA
presentation slide show ppt Select slide show viewing mode.
Ibogaine User Self-Help Groups: Cross Cultural Development
Dimitri Mobengo Mugianis -- Founding member, NYCAHN/VOCAL, NYC Drug Users Union. USA
An exploratory study of the short term effects of Ibogaine Treatment. Ibogaine Demographics.
Dr Anwar Jeewar, BDS, HRST, MSocSc -- Director - Minds Alive. South Africa
Minds Alive presentation - Ibogaine Demographics, PDF format
The Benefits & Risks of Treating with Ibogaine in a Clinical Setting: 3 Case Studies
Clare S. Wilkins -- Director, Pangea Biomedics. Mexico
Bwiti and iboga, Working properly and safely with iboga or ibogaine and Ibogaine antidotes
Patrick Moughenda Mickala, Nganga, Massango and Mitsogho tribe, Gabon
Description of the Ibogaine Session
The discovery of ibogaine's use as an anti-addictive from the West African plant, Tabernanthe
iboga, has been principally championed by drug user advocates in the United States, Canada, Brazil,
Mexico, New Zealand, Australia, Slovenia, Indonesia, Gabon and South Africa. Some scenes have grown while
others have declined. After decades of drug availability suddenly supplies of ibogaine used in
treatment was interrupted. Botanical sources had to be found and manufacturing technologies
reevaluated by those skilled in the chemistry and manufacture. Amidst all of these changes, the
sharing of knowledge, cross cultural understanding and the debt long owed to Africa was acknowledged
precipitating the organization of a Federation of Worldwide Ibogaine Practitioners. This panel is
Major clinics are thriving from Mexico to South Africa, clinical trials are pending in Israel and
India, and new clinical research is being contemplated in New Zealand, S. Africa, and South
America principally for indications to addiction though antibacterial and antiviral effects have
been noted. Underground user self-help organizations in keeping with AA except they are not
abstinence based are growing in cities where ibogaine is not generally available. What are ibogaine's
potential benefits to society? And what are hindrances to manufacturing, accessing, and researching
this unique substance? How does it work? What are its mechanisms of action in treating narcotic withdrawal? We
herewith present the most exhaustive conference panel on ibogaine ever held. We gladly invite you to
2009 International Drug Policy Reform conference web page
Return to Calendar of Ibogaine Conferences, Forums and Meetings
Return to What's New
What's new |